Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10729768
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted -
US 10729774
Pharmaceutical compositions comprising meloxicam
granted -
US 10729767
Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage
granted -
US 10729756
Viable viruses with foreign tags
granted -
US 10729725
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 10729773
Pharmaceutical compositions comprising meloxicam
granted -
US 10729697
Pharmaceutical compositions comprising meloxicam
granted -
US 10729747
Methods and compositions for modulating myofibroblast activities
granted -
US 10729696
Pharmaceutical compositions comprising meloxicam
granted -
US 10729736
Composition for reducing blood lipid and use thereof as healthcare dietary supplements
granted -
US 10729693
Compositions and methods for the treatment of endometriosis
granted -
US 10729650
Skin punch biopsy and wound-debridgement training model
granted -
US 10729676
Opioid agonist peptides and uses thereof
granted -
US 10729668
Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
granted -
US 10729643
Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
granted -
US 10729624
High-ultraviolet absorption lignin/chemical sun-screening agent microcapsule and preparation method therefor
granted -
US 10729641
Ordered macroporous materials
granted -
US 10729534
Methods of treating a musculoskeletal tissue interface injury using decellularized composite tissue bioscaffolds
granted -
US 10729651
Sustained release formulation of a non-steroidal anti-inflammatory drug
granted -
US 10729681
Prolyl hydroxylase inhibitors and methods of use
granted -
US 10729720
Peroxide formulations and methods and applicators for using the same
granted -
US 10729753
Compositions and methods for treatment of homocystinuria
granted -
US 10729815
Combined treatment for nerve injuries
granted -
US 10730842
Small molecule inhibitors of DYRK1A and uses thereof
granted -
US 10730925
Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
granted -
US 10730941
Antigen-binding proteins targeting CD56 and uses thereof
granted -
US 10730948
Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
granted -
US 10731154
Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
granted -
US 10731172
Regulating alkaloids
granted -
US 10729688
Hepatitis B antiviral agents
granted -
US 10731131
Dendritic cell generator
granted -
US 10730882
2-aminoquinazoline derivatives as P70S6 kinase inhibitors
granted -
US 10730929
Serpin fusion polypeptides and methods of use thereof
granted -
US 10731116
Alcoholic compositions having a lowered risk of acetaldehydemia
granted -
US 10730944
Anti-CD8 antibodies and uses thereof
granted -
US 10730871
Immunomodulators and immunomodulator conjugates
granted -
US 10730949
Method of treating PVNS with anti-CSF1R antibodies
granted -
US 10730854
Therapeutically active compounds and their methods of use
granted -
US 10730848
Protective molecules against anthrax toxin
granted -
US 10730837
Modified amino acids
granted -
US 10729895
Active agent delivery devices and methods of using the same
granted -
US 10730835
Thalidomide analogs and methods of use
granted -
US 10730831
Selective androgen receptor modulators (SARMs) and uses thereof
granted -
US 10729788
Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
granted -
US 10730834
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted -
US 10738116
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
granted -
US 10738124
Anti-EGFRvIII antibodies and uses thereof
granted -
US 10738126
Anti-GITR antibodies and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.